Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner

ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The BioCentury Show, Genge discusses progress in pathway prioritization, progression-rate prediction, and endpoint standardization with BioCentury's Selina Koch.On the biology side, Genge expects the field to converge on a small number of high-priority pathways. SOD1 is the first validated example, and AL-S Pharma is now testing whether misfolded SOD1 marks a treatable subset of sporadic ALS. On biomarkers, she's optimistic a TDP-43 marker could arrive within two years.View full story: https://www.biocentury.com/article/659713 #ALS #DrugDevelopment #ClinicalTrials #Biomarkers #ALSResearch00:00 - Introduction02:03 - ALS Mechanistic Diversity06:13 - Trial Design Challenges16:52 - Biomarker Toolkit Update24:20 - ALS Pharma & SOD1